Repeal of Directive 2001/20/EC on medicinal products for human use

This procedure updates the rules for conducting clinical trials for medicines in the EU. It aims to harmonize trial processes across member states, making it easier to get new treatments approved and ensuring high standards of safety and ethics for participants.

The updated regulation will affect researchers, pharmaceutical companies, and patients. It seeks to streamline approvals, improve data transparency, and ultimately accelerate the availability of safe and effective new medicines for all EU citizens.